Clinical Pharmacokinetics

, Volume 53, Issue 6, pp 489–507 | Cite as

Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins

  • Mario Regazzi
  • Anna Cristina Carvalho
  • Paola Villani
  • Alberto Matteelli
Review Article

Abstract

Tuberculosis (TB) and HIV continue to be two of the major causes of morbidity and mortality in the world, and together are responsible for the death of millions of people every year. There is overwhelming evidence to recommend that patients with TB and HIV co-infection should receive concomitant therapy of both conditions regardless of the CD4 cell count level. The principles for treatment of active TB disease in HIV-infected patients are the same as in HIV-uninfected patients. However, concomitant treatment of both conditions is complex, mainly due to significant drug–drug interactions between TB and HIV drugs. Rifamycins are potent inducers of the cytochrome P450 (CYP) pathway, leading to reduced (frequently sub-therapeutic) plasma concentrations of some classes of antiretrovirals. Rifampicin is also an inducer of the uridine diphosphate glucuronosyltransferase (UGT) 1A1 enzymes and interferes with drugs, such as integrase inhibitors, that are metabolized by this metabolic pathway. Rifampicin is also an inducer of the adenosine triphosphate (ATP) binding cassette transporter P-glycoprotein, which may also lead to decreased bioavailability of concomitantly administered antiretrovirals. On the other side, rifabutin concentrations are affected by the antiretrovirals that induce or inhibit CYP enzymes. In this review, the pharmacokinetic interactions, and the relevant clinical consequences, of the rifamycins—rifampicin, rifabutin, and rifapentine—with antiretroviral drugs are reviewed and discussed. A rifampicin-based antitubercular regimen and an efavirenz-based antiretroviral regimen is the first choice for treatment of TB/HIV co-infected patients. Rifabutin is the preferred rifamycin to use in HIV-infected patients on a protease inhibitor-based regimen; however, the dose of rifabutin needs to be reduced to 150 mg daily. More information is required to select optimal treatment regimens for TB/HIV co-infected patients whenever efavirenz cannot be used and rifabutin is not available. Despite significant pharmacokinetic interactions between antiretrovirals and antitubercular drugs, adequate clinical response of both infections can be achieved with an acceptable safety profile when the pharmacological characteristics of drugs are known, and appropriate combination regimens, dosing, and timing of initiation are used. However, more clinical research is needed for newer drugs, such as rifapentine and the recently introduced integrase inhibitor antiretrovirals, and for specific population groups, such as children, pregnant women, and patients affected by multidrug-resistant TB.

Notes

Conflict of interest

No sources of funding were used in the preparation of this review. Mario Regazzi, Anna Cristina Carvalho, Paola Villani and Alberto Matteelli have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    World Health Organization (WHO). Global tuberculosis report 2013. WHO/HTM/TB/2013.11. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf. Accessed 3 Jan 2014.
  2. 2.
    UNAIDS. UNAIDS report on the global AIDS epidemic 2013. UNAIDS/JC2502/1/E. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed 3 Jan 2014.
  3. 3.
    World Health Organization (WHO). Treatment of tuberculosis guidelines. Fourth edition. 2010. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf. Accessed 3 Jan 2014.
  4. 4.
    International Standards for Tuberculosis Care (ISTC), 2nd ed. The Hague: Tuberculosis Coalition for Technical Assistance; 2009. http://www.currytbcenter.ucsf.edu/international/istc_report_2nded.pdf. Accessed 3 Jan 2014.
  5. 5.
    Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 3 Jan 2014.
  6. 6.
    World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection—recommendations for a public health approach. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. Accessed 3 Jan 2014.
  7. 7.
    Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi: 10.1371/journal.pmed.1001270.
  8. 8.
    Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource limited settings. Clin Chest Med. 2009;30:685–99.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697–706.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–81.PubMedGoogle Scholar
  11. 11.
    Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Abdool Karim SN, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365:1492–501.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, Schünemann HJ, et al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One. 2012;7:e47370. doi: 10.1371/journal.pone.0047370.PubMedCentralPubMedGoogle Scholar
  14. 14.
    World Health Organization (WHO). WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and other stakeholders. http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf. Accessed 3 Jan 2014.
  15. 15.
    McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196(Suppl 1):S63–75.PubMedGoogle Scholar
  16. 16.
    Gengiah TN, Gray AL, Naidoo K, Karim QA. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf. 2011;10:559–74.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Ahmad Khan F, Minion J, Al-Motairi A, Benedetti A, Harries AD, Menzies D. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis. 2012;55:1154–63.PubMedGoogle Scholar
  18. 18.
    Nunn AJ, Jindani A, Enarson DA, Study A investigators. Results at 30 months of a randomized trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15:741–5.PubMedGoogle Scholar
  19. 19.
    Matteelli A, Richardson MD, Sotgiu G, Centis R, Migliori GB. Multidrug- and extensively drug-resistant TB in persons living with HIV. Exp Rev Respir Med. 2009;3:245–54.Google Scholar
  20. 20.
    Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.PubMedGoogle Scholar
  21. 21.
    Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516–28.PubMedGoogle Scholar
  22. 22.
    da Silva PA, Aínsa JA. Drugs and drug interactions. Chapter 18. In: Palomino JC, Cardoso Leão S, Ritacco V. Tuberculosis 2007-from basic science to patient care. pp. 593–634. http://www.TuberculosisTextbook.com. Accessed 3 Jan 2014.
  23. 23.
    Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations—part 1: first-line drugs. J Bras Pneumol. 2010;36:626–40.PubMedGoogle Scholar
  24. 24.
    Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126–36.PubMedGoogle Scholar
  25. 25.
    Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819–50.PubMedGoogle Scholar
  26. 26.
    Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampicin is a selective, pleiotropic inducer of drug metabolism: studies with cDNA and oligonucleotide expression assays. J Pharmacol Exp Ther. 2001;299:849–57.PubMedGoogle Scholar
  27. 27.
    Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57:6366–9.PubMedGoogle Scholar
  28. 28.
    Magnusson MO. Pharmacodynamics of enzyme induction and its consequences for substrate elimination [thesis]. Uppsala: Uppsala Universitet; 2007. Distribution: publications.uu.seurn:nbn:se:uu:diva-7812.Google Scholar
  29. 29.
    Magnusson MO, Karlsson MO, Sandström R. A mechanism based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. Pharm Res. 2006;23:521–32.PubMedGoogle Scholar
  30. 30.
    Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53:2852–6.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147–53.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996;22(Suppl):S15–22.PubMedGoogle Scholar
  33. 33.
    Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, Koudriakova T. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther. 1997;61(5):554–62.PubMedGoogle Scholar
  34. 34.
    Keung ACF, Owens RC Jr, Eller MG, Weir SJ, Nicolau DP, Nightingale CH. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Antimicrob Agents Chemother. 1999;43(5):1230.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Rastogi N, Goh KS, Berchel M, Bryskier AJ. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. Antimicrob Chemother. 2000;46(4):565–70.Google Scholar
  36. 36.
    Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327–41.PubMedGoogle Scholar
  37. 37.
    Rifapentine—a long-acting rifamycin for tuberculosis. Med Lett Drugs Ther 1999;41:21–2.Google Scholar
  38. 38.
    Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006;43:1468–1475.Google Scholar
  39. 39.
    Keung A, Reith K, Eller MG, McKenzie KA, Cheng L, Weir SJ. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis. 1999;3:426–36.PubMedGoogle Scholar
  40. 40.
    Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3:108–27.PubMedGoogle Scholar
  41. 41.
    Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360:528–34.PubMedGoogle Scholar
  42. 42.
    Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis trials consortium. Lancet. 1999;353:1843–7.PubMedGoogle Scholar
  43. 43.
    Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167:1341–7.PubMedGoogle Scholar
  44. 44.
    Centers for Disease Control. Managing drug interactions in the treatment of HIV-related tuberculosis. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/pdf/tbhiv.pdf. Accessed 3 Jan 2014.
  45. 45.
    Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004;37(Suppl 1):S2–12.PubMedGoogle Scholar
  46. 46.
    Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol. 1999;48:168–79.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71–5.PubMedGoogle Scholar
  48. 48.
    Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009;14:687–95.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug–drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob Agents Chemother. 2013;57:1019–24.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, Nakayama EE, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther. 2010;7:8.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648–53.PubMedGoogle Scholar
  52. 52.
    Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58:1299–302.PubMedGoogle Scholar
  53. 53.
    López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681–90.PubMedGoogle Scholar
  54. 54.
    Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, et al. Multiple dose pharmacokinetics of efevirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res. 2007;5:349–53.PubMedGoogle Scholar
  55. 55.
    Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother. 2009;53:863–8.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530–9.PubMedGoogle Scholar
  57. 57.
    Matteelli A, Carvalho AC, Apostoli A, Tinelli C, Scudeller L, El Hamad I et al. Completion rate and viro-immunological response to combined TB/HIV treatment: results from the RIFART study [abstract no. 854]. 20th Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2013; Atlanta.Google Scholar
  58. 58.
    Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011;25:388–90.PubMedGoogle Scholar
  59. 59.
    Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20:131–2.PubMedGoogle Scholar
  60. 60.
    Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocaña I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28:450–3.PubMedGoogle Scholar
  61. 61.
    Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61:389–93.PubMedGoogle Scholar
  62. 62.
    Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005;10:937–43.PubMedGoogle Scholar
  63. 63.
    Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol. 2009;65:71–80.PubMedGoogle Scholar
  64. 64.
    Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, N2R Study Team, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009;48:1752–9.PubMedGoogle Scholar
  65. 65.
    Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, et al. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. J Acquir Immune Defic Syndr. 2009;52:64–9.PubMedGoogle Scholar
  66. 66.
    van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther. 2007;12:515–21.PubMedGoogle Scholar
  67. 67.
    Moses M, Zachariah R, Tayler-Smith K, Misinde D, Foncha C, Manzi M, et al. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. Int J Tuberc Lung Dis. 2010;14:197–202.PubMedGoogle Scholar
  68. 68.
    Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13:529–36.PubMedGoogle Scholar
  69. 69.
    Manosuthi W, Tantanathip P, Chimsuntorn S, Eampokarap B, Thongyen S, Nilkamhang S, Sungkanuparph S. Treatment outcome of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. Int J Infect Dis. 2010;14:1013–7.Google Scholar
  70. 70.
    Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53:716–24.PubMedGoogle Scholar
  71. 71.
    Sinha S, Raghunandan P, Chandrashekhar R, Sharma S, Kumar S, Dhooria S et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. BMC Infect Dis 2013;13:482. http://www.biomedcentral.com/1471-2334/13/482.
  72. 72.
    Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis. 2013;13:303–12.PubMedGoogle Scholar
  73. 73.
    Benedek IH, Fiske WD, White SJ, Stevenson J, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz (EFV) and rifabutin in healthy volunteers [abstract no. 461]. In: Program and abstracts of the Infectious Diseases Society; 12–15 Nov 1998; Denver.Google Scholar
  74. 74.
    Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis. 2005;41:1343–9.PubMedGoogle Scholar
  75. 75.
    Maldonado S, Lamson M, Gigliotti M, et al. Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifabutin (RFB) [abstract no. 341]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 26–29 Sep 1999; San Francisco.Google Scholar
  76. 76.
    Van Heeswijk R, Hoetelmans RMW, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) [abstract no. 74]. 7th International Workshop of Clinical Pharmacology; 20–22 Apr 2006; Lisbon.Google Scholar
  77. 77.
    Crauwels H, van Heeswijk R, Kestens D, et al. The pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) [abstract no. TUPE0080]. 17th International AIDS Conference; 3–8 Aug 2008; Mexico City.Google Scholar
  78. 78.
    Crauwels H, van Heeswijk RP, Stevens M, Buelens A, Vanveggel S, Boven K, Hoetelmans R. Clinical perspective on drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87–101.PubMedGoogle Scholar
  79. 79.
    Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50:25–39.PubMedGoogle Scholar
  80. 80.
    Kakuda TN, Woodfall B, De Marez T, Peeters M, Vandermeulen K, Aharchi F, Hoetelmans RM. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother. 2014;69(3):728–34. doi: 10.1093/jac/dkt421.PubMedGoogle Scholar
  81. 81.
    Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther. 1997;61:544–53.PubMedGoogle Scholar
  82. 82.
    Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res. 1997;35:53–63.PubMedGoogle Scholar
  83. 83.
    Centers for Disease Control and Prevention (CDC). Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep. 1996;45:921–5.Google Scholar
  84. 84.
    Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3336–42.PubMedCentralPubMedGoogle Scholar
  85. 85.
    Goutelle S, Baudry T, Gagnieu MC, Boibieux A, Livrozet JM, Peyramond D, et al. Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients. Antimicrob Agents Chemother. 2013;57(1):517–23.PubMedCentralPubMedGoogle Scholar
  86. 86.
    la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:1553–60.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G. Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets. Antimicrob Agents Chemother. 2011;55:3195–200.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Grange SM, Schutz C, Schmitt M, Gaudeul-Ehrhart R. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted sequinavir and vice versa [abstract no. 35]. 6th International Workshop on Clinical Pharmacology and HIV Therapy; 28–30 Apr 2005; Montreal.Google Scholar
  89. 89.
    Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr. 2009;50:290–3.PubMedCentralPubMedGoogle Scholar
  90. 90.
    Nijland HM, L’homme RF, Rongen GA, van Uden P, van Crevel R, Boeree MJ, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008;22:931–5.PubMedGoogle Scholar
  91. 91.
    Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron E. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PloS One. 2012;7:e32173. doi: 10.1371/journal.pone.0032173.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath H. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One. 2012;7:e44793. doi: 10.1371/journal.pone.0044793.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Loeliger A, Suthar AB, Ripin D, Glaziou P, O’Brien M, Renaud-Thery F, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis. 2012;16:6–15.PubMedGoogle Scholar
  94. 94.
    Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007;(4):CD005159.Google Scholar
  95. 95.
    Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis. 1994;75:341–7.PubMedGoogle Scholar
  96. 96.
    McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154:1462–7.PubMedGoogle Scholar
  97. 97.
    Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, Apostoli A, et al. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother. 2012;67:2470–3.PubMedGoogle Scholar
  98. 98.
    Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. MMWR Recomm Rep. 2004;53(15):1–112.Google Scholar
  99. 99.
    Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009;49:1305–11.PubMedGoogle Scholar
  100. 100.
    Khachi H, O’Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother. 2009;64:871–3.PubMedGoogle Scholar
  101. 101.
    Tanuma J, Sano K, Teruya K, Watanabe K, Aoki T, Honda H, et al. Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy. PLoS One. 2013;8:e70611. doi: 10.1371/journal.pone.0070611.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481–91.PubMedGoogle Scholar
  103. 103.
    Jenny-Avital E, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis. 2009;48:1471–4.PubMedGoogle Scholar
  104. 104.
    Lan NT, Thu NT, Barrail-Tran A, Duc N, Lan NN, Laureillard D, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014;9(1):e84866. doi: 10.1371/journal.pone.0084866.
  105. 105.
    Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother. 2011;66:2075–82.PubMedGoogle Scholar
  106. 106.
    Ramachandran G, Bhavani PK, Hemanth Kumar AK, Srinivasan R, Raja K, Sudha V, et al. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. Int J Tuberc Lung Dis. 2013;17:1564–8.PubMedGoogle Scholar
  107. 107.
    Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54:4440–5.PubMedCentralPubMedGoogle Scholar
  108. 108.
    Ford SL, Chen YC, Lou Y, Borland J, Min S, Yuen GJ, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother. 2008;52:534–8.PubMedCentralPubMedGoogle Scholar
  109. 109.
    la Porte CJL, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother. 2009;53:162–73.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Burger DM, Magis-Escurra C, van den Berk GE, Gelinck LB. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS. 2010;24:328–30.PubMedGoogle Scholar
  111. 111.
    Mena A, Vázquez P, Castro Á, López S, Bello L, Pedreira JD. Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis. J Antimicrob Chemother. 2011;66:951–2.PubMedGoogle Scholar
  112. 112.
    French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS). Efficacy and safety of 2 raltegravir doses in naive HIV-1-infected patients receiving rifampin for active tuberculosis. http://clinicaltrials.gov/show/NCT00822315 Accessed 3 Jan 2014.
  113. 113.
    Grinsztejn B, De Castro N, Arnold V, et al. A randomized multicentre open-label trial to estimate the efficacy and safety of two doses of raltegravir (RAL) to efavirenz (EFV) for the treatment of HIV-TB co-infected patients: results of the ANRS 12 180 Reflate TB trial [abstract no. THLBB01]. In: Program and Abstracts of the XIX International AIDS Conference; 22–27 Jul 2012; Washington, DC.Google Scholar
  114. 114.
    Brainard DM, Kassahun K, Wenning LA, Pety AS, Liu C, Lunceford J, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol. 2011;51:943–50.PubMedGoogle Scholar
  115. 115.
    Lee JS, Calmy A, Andrieux-Meyer I, Ford N. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV AIDS. 2012;4:5–15.Google Scholar
  116. 116.
    German P, West S, Hui J, Kearney BP. Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted rifabutin [abstract no. P19]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7–9 Apr 2008; New Orleans.Google Scholar
  117. 117.
    Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-EFV with atazanavir, rosuvastatin or rifabutin [abstract no. O-03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 16–18 Apr 2012; Barcelona.Google Scholar
  118. 118.
    Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–7.PubMedGoogle Scholar
  119. 119.
    Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33:587–95.PubMedGoogle Scholar
  120. 120.
    Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl. 1):38–46.PubMedCentralPubMedGoogle Scholar
  121. 121.
    Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44:175–86.PubMedGoogle Scholar
  122. 122.
    Boyd MA, Zhang X, Dorr A, Ruxrungtham K, Kolis S, Nieforth K, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol. 2003;43:1382–91.PubMedGoogle Scholar
  123. 123.
    Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 2012;35:113–59.PubMedGoogle Scholar
  124. 124.
    Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–61.PubMedGoogle Scholar
  125. 125.
    Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010;11:334–44.PubMedGoogle Scholar
  126. 126.
    Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, et al. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis. 2010;201:106–13.PubMedGoogle Scholar
  127. 127.
    Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566–9.PubMedGoogle Scholar
  128. 128.
    Elsherbiny D, Ren Y, McIlleron H, Maartens G, Simonsson US. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol. 2010;66:1017–23.PubMedGoogle Scholar
  129. 129.
    Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, Meyers T. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011;6:e17273. doi: 10.1371/journal.pone.0017273.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART. AIDS. 2011;25:49–55.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Mario Regazzi
    • 1
  • Anna Cristina Carvalho
    • 2
    • 3
  • Paola Villani
    • 1
  • Alberto Matteelli
    • 2
  1. 1.Unit of Clinical and Experimental PharmacokineticsFoundation IRCCS Policlinico San MatteoPaviaItaly
  2. 2.Institute of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-infectionUniversity of BresciaBresciaItaly
  3. 3.Laboratory of Innovations in Therapies, Education and Bioproducts (LITEB), Oswaldo Cruz Institute (IOC)Oswaldo Cruz Foundation (Fiocruz)Rio de JaneiroBrazil

Personalised recommendations